Introduction: Standards of antibacterial performance

Clinical Microbiology and Infection

Volumn 10, Issue SUPPL. 2, 2004, Pages 1-5

  Finch, R G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antibiotic prescribing; Drug development; Drug resistance; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG DESIGN; DRUG MONITORING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; LICENSING; NONHUMAN; OUTCOMES RESEARCH; PATIENT ATTITUDE; PENICILLIN RESISTANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STANDARDIZATION; STREPTOCOCCUS PNEUMONIAE; SUSTAINED RELEASE FORMULATION;

POSIBACTERIA;

EID: 1242314050     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1470-9465.2004.00861.x     Document Type: Article

References (21)

1. World Health Organisation. Report on Infectious Diseases. Removing Obstacles to Healthy Development. Geneva: World Health Organisation, 1999; http://www.who.int/infectious-diseases-report.html accessed March 2003.
2. MacFarlane J, Boswell T, Douglas G et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56: iv1-iv64.
3. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123: S1-S31.
4. Miravitlles M, Murio C, Guerrero T, Gisbert R, DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.
5. Bartlett JG, Dowell SF, Mandell LA et al. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
6. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (Suppl. 6): 310S-313S.
7. World Health Organisation. Global Strategy for the Containment of Antimicrobial Resistance. Geneva: World Health Organisation, 2001; http://www.who.int/emc accessed March 2003.
8. Mandell LA. Relationship of penicillin resistance to mortality in pneumococcal pneumonia. Curr Infect Dis Rep 2001; 3: 9-12.
9. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
10. Huff J, White A, Power E, Weil J, Mera R. 10-year trends in penicillin- and erythromycin-resistant S. pneumoniae for 5 European countries and the USA. The Alexander Project [abstract C2-1624]. In: Abstracts from the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA: American Society of Microbiology, 2002; 108.
11. Smith RD, Coast J. Antimicrobial resistance: a global response. Bull World Health Organ 2002; 80: 126-132.
12. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
13. Cars O. Steering an appropriate course: principles to guide antibiotic choice. Respir Med 2001; 95 (Suppl. A): S20-S25.
14. Smith RD, Coast J, Millar MR, Witon P, Karcher A-M. Interventions Against Antimicrobial Resistance: A Review of the Literature and Exploration of Modelling Cost-effectiveness. Geneva: World Health Organisation, 2001; http://www.who.int/emc/amrpdfs/ interventions_against_antimicrobial_resistance.pdf accessed March 2003.
15. Centers for Disease Control and Prevention. Appropriate Antibiotic Use in Upper Respiratory Tract Infections. Atlanta, GA: Centers for Disease Control and Prevention, 2002; http://www.cdc.gov/drugresistance/community/ accessed February 2003.
16. Commission of the European Communities. Communication from the Commission on a Community Strategy Against Antimicrobial Resistance. Brussels: Commission of the European Communities, 2001.
17. Standing Medical Advisory Committee. The Path of Least Resistance. London: UK Department of Health, 1997.
18. Craig WA. Re-evaluating current antibiotic therapy. Respir Med 2001; 95 (Suppl. A): S12-S19.
19. Committee for Proprietary Medicinal Products. Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products. London: European Medicines Evaluation Agency, 2000; http://www.emea.eu.International/pdfs/human/ewp/265599en.pdf accessed August 2003.
20. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
21. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 (Suppl. 1): S13-S20.